Butirilcolinesterase e diabetes melito nos fenótipos CHE2 C5- e CHE2 C5+;Butyrylcholinesterase and diabetes mellitus in the CHE2 C5-and CHE2 C5+ phenotypes

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 54, Issue 1, 2010, Pages 60-67

  Cwiertnia, Mauro M ^a   Alcântara, Vânia M ^a   Réa, Rosângela R ^a   Faria, Ana Cristina R A ^a   Picheth, Geraldo ^a   Scartezini, Marileia ^a   Graef, Lorena E ^a   Welter, Marciane ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

BCHE and CHE2 loci; C4 5, Complexes; Insulin resistance; Metabolic syndrome; Obesity; Serum cholinesterase

Indexed keywords

CHOLINESTERASE; CHOLINESTERASE 2;

ADULT; ARTICLE; BLOOD; BODY MASS; BODY WEIGHT; CASE CONTROL STUDY; ENZYMOLOGY; FEMALE; GENETICS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PHENOTYPE; PHYSIOLOGY; REGRESSION ANALYSIS;

ADULT; BODY MASS INDEX; BODY WEIGHT; BUTYRYLCHOLINESTERASE; CASE-CONTROL STUDIES; CHOLINESTERASES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PHENOTYPE; REGRESSION ANALYSIS;

EID: 77952870219     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/s0004-27302010000100011     Document Type: Article

References (45)

1. Masson P, Chatonnet A, Lockridge O. Evidence for a single butyrylcholinesterase gene in individuals carrying the C5 plasma cholinesterase variant (CHE2). FEBS Lett. 1990;262(1):115-8.
2. Chautard-Freire-Maia EA, Primo-Parmo SL, Picheth G, Lourenço MA, Vieira MM. The C5 isozyme of serum cholinesterase and adult weight. Hum Hered. 1991;41(5):330-9.
3. Harris H. The principles of human biochemical genetics. Amsterdam, Elsevier/North-Holland Biomedical; 1980.
4. Alcântara VM, Oliveira LC, Réa RR, Suplicy HL, Chautard-Freire-Maia EA. Butyrylcholinesterase and obesity in individuals with the CHE2 C5+ and CHE2 C5- phenotypes. Int J Obes Relat Metab Disor. 2003;27(12):1557-64.
5. Souza RL, Furtado L, Diniz AC, Silva AC, Kaiss J, Petzl-Erler ML, et al. Studies on a heterologous complex formed by human butyrylcholinesterase. Biochem Genet. 2003;41(5-6):141-50.
6. Antopol W, Tuchman L, Schifrin A. Cholinesterase activity of human sera with special reference to hyperthyroidism. Proc Soc Exp Biol Med. 1937;36:46-50.
7. Alcântara VM, Chautard-Freire-Maia EA, Scartezin M, Cerci MS, Braun-Prado K, Picheth G. Butyrylcholinesterase activity and risk factors for coronary artery disease. Scand J Clin Lab Invest. 2002;62(5):399-404.
8. Cucuianu M, Popescu TA, Opincaru A, Haragus S. Serum pseudocholinesterase and ceruloplasmin in various types of hyperlipoproteinemia. Clin Chem Acta. 1975;59(1):19-27.
9. Crook M, Haq M, Tutt P. Serum lipids, acute phase proteins and serum cholinesterase in normal subjects. Scand J Clin Lab Invest. 1994;54(8):601-3.
10. Magarian EO, Dietz AJ. Correlation of cholinesterase with serum lipids and lipoproteins. J Clin Pharmacol. 1987;27(10):819-20.
11. Simpson NE. Factors influencing cholinesterase activity in a Brazilian population. Am J Hum Genet. 1966;18(3):243-52.
12. Kutty KM, Jain R, Huang S, Kean K. Serum pseudocholinesterase: high density lipoprotein cholesterol ratio as an index of risk for cardiovascular disease. Clin Chim Acta. 1981;115(1):55-61.
13. Alcântara VM, Oliveira LC, Réa RR, Suplicy HL, Chautard-Freire- Maia EA. Butyrylcholinesterase activity and metabolic syndrome in obese patients. Clin Chem Lab Med. 2005;43(3):285-8.
14. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2003;26:Suppl 1:S5-S20.
15. Bierman EL. George Lyman Duff Memorial Lecture. Atherogenesis in diabetes. Arterioscler Thromb Vasc Biol. 1992;12:647-56.
16. Brochu M, Poehlman ET, Ades PA. Obesity, body fat distribution, and coronary artery disease. J Cardiopulm Rehabil. 2000;20(2):96-108.
17. Nagaretani H, Nakamura T, Funahashi T, Kotani K, Miyanaga M, Tokunaga K, et al. Visceral fat is a major contributor for multiple risk factors clustering in Japanese men with impaired glucose tolerance. Diabetes Care. 2001;24(12):2127-33.
18. Pascot A, Despres JP, Lemieux I, Bergeron J, Nadeau A, Prud'homme D, et al. Contribution of visceral obesity to the deterioration of the metabolic risk profile in men with impaired glucose intolerance. Diabetologia. 2000;43:1126-35.
19. Colditz GA, Willett WC, Stampfer MJ, Manson JE, Hennekens CH, Arky RA, et al. Weight as a risk factor for clinical diabetes in women. Am J Epidemiol. 1990;132(3):501-13.
20. Maison P, Byrne CD, Hales CN, Day NE, Wareham NJ. Do different dimensions of the metabolic syndrome change together over time? Evidence supporting obesity as the central feature. Diabetes Care. 2001;24(10):1758-63.
21. Abbott CA, Mackness MI, Kumar S, Olukoga AO, Gordon C, Arrol S et al. Relationships between serum butyrylcholinesterase activity, hypertriglyceridaemia and insulin sensitivity in diabetes mellitus. Clin Sci. 1993;85:77-81.
22. Taskinen MR. Quantitative and qualitative lipoprotein abnormalities in diabetes mellitus. Diabetes. 1992;41: Suppl 2:12-7.
23. Steinberg D, Gotto AM Jr. Preventing coronary artery disease by lowering cholesterol levels: fifty years from bench to bedside. JAMA. 1999;282(21):2043-50.
24. Frohlich J, Dobiasova M. Fractional esterification rate of cholesterol and ratio of triglycerides to HDL-cholesterol are powerful predictors of positive findings on coronary angiography. Clin Chem. 2003;49(11):1873-80.
25. Dietz AA, Rubinstein HM, Lubrano T. Colorimetric determination of serum cholinesterase and its genetic variants by the propionylthiocholine- dithiobis (nitrobenzoic acid) procedure. Clin Chem. 1973;19(11):1309-13.
26. Evans RT, Wroe J. Is serum cholinesterase activity a predictor of succinylcholine sensitivity? An assessment of four methods. Clin Chem. 1978;24(10):1762-66.
27. Van Ros G, Vervoort T. Frequencies of the atypical and C5 variants of serum cholinesterase in Zairians and Belgians. Detection of the C5 variant by agar gel electrophoresis with an acid buffer. Ann Soc Belg Med Trop. 1973;53:633-44.
28. Kodak Digital. Corel Photo Paint 9. New York, 1995-1997, 1 CD-ROM.
29. Kodak ID. Image Analyses Software for Windows. New York, v. 3.5, 1994-2000, 1 CD-ROM.
30. Statsoft. Microsoft, Inc. Statistica for Windows. Tulsa, 1996. 1CD-ROM.
31. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-9.
32. Alcântara VM, Rodrigues, LC, Oliveira, LC, Chautard-Freire-Maia EA. Association of the CHE2 locus with body mass index and butyrylcholinesterase activity. Hum Biol. 2001;73:587-95.
33. Propert DN, Brackenridge CJ. The relation of sex, age, smoking status, birth rank and parental ages to pseudocholinesterase activity and phenotypes in a sample of Australian Caucasian adults. Hum Genet. 1976;32(2):181-8.
34. Alcântara VM, Rodrigues LC, Oliveira LC, Chautard-Freire-Maia EA. The variable expression of the C4/5 complex of human butyrylcholinesterase and body mass index. Hum Biol. 2003;75(1):47-55.
35. Sidell FR, Kaminskis A. Influence of age, sex, and oral contraceptives on human blood cholinesterase activity. Clin Chem. 1975;21(10):1393-5.
36. Shnider SM. Serum cholinesterase activity during pregnancy, labor and the puerperium. Anesthesiology. 1965;26:335-9.
37. Robertson GS. Serum cholinesterase deficiency. II: pregnancy. Br J Anaesth. 1966;38(5):361-9.
38. Kissebah AH, Vydelingum N, Murray R, Evans DJ, Hartz AJ, Kalkhoff RK, et al. Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab. 1982;54(2):254-60.
39. Ghiringhello MT, Vieira JG, Tachibana TT, Ferrer C, Maciel RM, Amioka PH, et al. Distribution of HOMA-IR in Brazilian subjects with different body mass indexes. Arq Bras Endocrinol Metab. 2006;50(3):573-4.
40. Cakan N, Ellis DA, Templin T, Frey M, Naar-King S. The effects of weight status on treatment outcomes in a randomized clinical trial of multisystemic therapy for adolescents with type 1 diabetes and chronically poor metabolic control. Pediatr Diabetes. 2007;8(4):206-13.
41. Xu P, Cuthbertson D, Greenbaum C, Palmer JP, Krischer JP. Role of insulin resistance in predicting progression to type 1 diabetes. Diabetes Care. 2007;30(9):2314-20.
42. Kissebah AH. Insulin resistance in visceral obesity. Int J Obes. 1991;15 Suppl 2:109-15.
43. Zavaroni I, Bonini L, Fantuzzi M, Dall'Aglio E, Passeri M, Reaven GM. Hyperinsulinaemia, obesity, and syndrome X. J Intern Med. 1994;235(5):51-6.
44. World Health Organization. BMI classification. [Homepage on the internet] [cited 2009 sep 9]. Available from: http://www.who.int/bmi/index.jsp?introPage=intro_3.html
45. Iwasaki T, Yoneda M, Nakajima A, Terauchi Y. Serum butyrylcholinesterase is strongly associated with adiposity, the serum lipid profile and insulin resistance. Intern Med. 2007;46(19):1633-9.